4basebio

Historical price data

4basebio is an innovation-driven biotech focused on accelerating advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral delivery platform. The company's core technology, TruePrime®, is a primer-free, enzymatic DNA amplification process that eliminates bacterial sequences and antibiotic resistance genes, offering a cleaner, faster, and more scalable alternative to plasmid DNA. With a recent CEO transition and a key supply agreement leading to a partner's clinical trial, 4basebio is positioning itself as a critical enabler for next-generation genetic medicines, from research through GMP-grade commercial production.

Proprietary, cell-free enzymatic DNA manufacturing platform (TruePrime®) that produces high-purity synthetic DNA (opDNA®) without bacterial sequences, serving as a superior alternative to plasmid DNA for mRNA production, viral vectors, and gene editing.

4basebio competes against traditional plasmid DNA manufacturers (e.g., Aldevron, Charles River) and other synthetic DNA/RNA synthesis companies (e.g., Twist Bioscience, Codex DNA). Its differentiation is based on its proprietary TruePrime® enzymatic process that produces long, clean, GMP-grade DNA without bacterial sequences, a claim now bolstered by clinical-stage validation with a major partner.